Haohai Biotechnology (06826) holding subsidiary's three-focus ring curved intraocular lens products obtained medical device registration certificate

Zhitong Finance App News, Haohai Biotech (06826) announced that the company's holding subsidiary, Henan Sameishi Biotechnology Co., Ltd. (hereinafter referred to as “Samex”), recently received the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration for trifocal curved intraocular lens products.

This product passed the national special approval process for innovative medical devices and became the first domestically produced trifocal astigmatism intraocular lens approved for marketing in China. The product innovatively combines trifocal diffraction optical design with curved surface astigmatism correction technology to improve the far-sightedness of cataract patients while effectively correcting corneal astigmatism, providing a more complete vision solution for patients with corneal astigmatism.

Following the launch of the multi-focus aspherical and Samex trifocal intraocular lenses of the company's subsidiary Henan Cosmic Artificial Lens Development Co., Ltd. during the year, the approval of this product further deepened the company's layout in the field of high-end refractive intraocular lenses. At this point, the company has formed a product matrix covering differentiated clinical needs such as single-focus and single-focus astigmatism correction, multifocus and multifocus astigmatism correction, which will enhance the company's comprehensive competitiveness in the high-end refractive cataract market and inject new momentum into the continuous and steady development of the ophthalmology business.